ProShare Advisors
PAVM icon

ProShare Advisors’s PAVmed PAVM Stock Holding History

ProShare Advisors’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30
Closed -$18K – 2028
2022
Q1 		$18K Sell
30
-5
-14% -$3.72K ﹤0.01% 2180
2021
Q4 		$40K Buy
+35
New +$76.1K ﹤0.01% 2305
2021
Q3 		– Sell
-41
Closed -$119K – 2192
2021
Q2 		$119K Buy
41
+4
+11% +$9.45K ﹤0.01% 2269
2021
Q1 		$74K Buy
+37
New +$55.6K ﹤0.01% 2197

Other funds holding PAVM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ProShare Advisors's PAVM Position: Q2 2022 in Review

ProShare Advisors sold out of PAVmed (PAVM) in Q2 2022, closing a stake of 30 shares — an estimated $18K sold.

ProShare Advisors first reported a position in PAVM in Q1 2021 and held it in 4 quarters. The position peaked at $119K in Q2 2021. 73 funds tracked by Wall St. Rank hold PAVM as of Q2 2022.

  • ProShare Advisors reported no remaining PAVmed position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 30 PAVmed shares in Q2 2022, an estimated $18K.
  • ProShare Advisors first reported a position in PAVmed in Q1 2021 and held it in 4 quarters.
  • ProShare Advisors's PAVmed position peaked at $119K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held PAVmed as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.